Companies Dominating the Hyaluronidase Power Injection Market
- Argenx SE
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- PrimaPharma, Inc.,
- Halozyme, Inc.
- Bausch & Lomb Incorporated
- The Cooper Companies Inc.,
- Sun Pharmaceutical Industries Ltd.
- STEMCELL Technologies Inc.
- Shijiazhuang Yiang Technology Co., Ltd.
- Calzyme
- Dermax Medical Technology (Hebei) Co., Ltd.
Browse Key Market Insights with Data Illustration:
In the News
- Argenx SE, an international immunology organization that works to modify the lives of people with serious autoimmune diseases, reported affirmative topline information from the Phase 3 ADAPT-SC study testing subcutaneous (SC) efgartigimod (1000 mg efgartigimod-PH20) as a therapy for generalized myasthenia gravis (gMG). Argenx delivered a biologics approval application (BLA) to the US FDA.
- The Food and Drug Administration (FDA) released a letter sanctioning the emergency utilization of the Alinity m Resp-4-Plex for the coexisting qualitative detection and distinction of RNA from SARS-CoV-2, influenza A virus (flu A), influenza B virus (flu B), and/or Respiratory Syncytial Virus (RSV) in anterior nasal or nasopharyngeal swab specimens accumulated by a healthcare provider (HCP).
